| For: | Chakrabarti S. Clozapine resistant schizophrenia: Newer avenues of management. World J Psychiatr 2021; 11(8): 429-448 [PMID: 34513606 DOI: 10.5498/wjp.v11.i8.429] |
|---|---|
| URL: | https://www.wjgnet.com/2220-3206/full/v11/i8/429.htm |
| Number | Citing Articles |
| 1 |
Anna S. Shumilova, Alla V. Kidyaeva, Regina F. Nasyrova. Evolution of the Concept of Treatment-Resistant Schizophrenia. Personalized Psychiatry and Neurology 2025; 5(2) doi: 10.52667/2712-9179-2025-5-2-37-48
|
| 2 |
Pamela Franco, Cristian Montalba, Raúl Caulier-Cisterna, Carlos Milovic, Alfonso González, Juan Pablo Ramirez-Mahaluf, Juan Undurraga, Rodrigo Salas, Nicolás Crossley, Cristian Tejos, Sergio Uribe. Interpretable machine learning model for characterizing magnetic susceptibility-based biomarkers in first episode psychosis. Computer Methods and Programs in Biomedicine 2025; 272 doi: 10.1016/j.cmpb.2025.109067
|
| 3 |
Marcin Siwek, Adrian Andrzej Chrobak, Aleksandra Gorostowicz, Patrycja Król, Dominika Dudek. Cariprazine augmentation of clozapine in schizophrenia—a retrospective chart review. Frontiers in Pharmacology 2024; 14 doi: 10.3389/fphar.2023.1321112
|
| 4 |
Ping-Tao Tseng, Mu-Hong Chen, Chih-Sung Liang. Difference between treatment-resistant schizophrenia and clozapine-resistant schizophrenia. World Journal of Psychiatry 2022; 12(8): 1102-1104 doi: 10.5498/wjp.v12.i8.1102
|
| 5 |
Phillipa Louise Brothwood, Mina Husain, Jessica Pinson, Ebenezer Oloyede, Patrick Davey, Eromona Whiskey. Clozapine in Combination With Olanzapine Long-Acting Injection. Journal of Clinical Psychopharmacology 2023; 43(5) doi: 10.1097/JCP.0000000000001746
|
| 6 |
Djenifer B. Kappel, Sophie E. Legge, Leon Hubbard, Isabella R. Willcocks, Kevin S. O’Connell, Robert L. Smith, Espen Molden, Ole A. Andreassen, Adrian King, John Jansen, Marinka Helthuis, Michael J. Owen, Michael C. O’Donovan, James T.R. Walters, Antonio F. Pardiñas. Genomic Stratification of Clozapine Prescription Patterns Using Schizophrenia Polygenic Scores. Biological Psychiatry 2023; 93(2) doi: 10.1016/j.biopsych.2022.07.014
|
| 7 |
Asmaa Fady Sharif, Zahraa Khalifa Sobh, Sanaa Abd El-Fatah Abdo, Osama M. Alahmadi, Hatem A. Alharbi, Mohannad Saif Awaji, Faris A. Alabdullatif, Abdullah M. Baghlaf, Ahmad F. Alanazi, Manar Maher Fayed. Evaluation of Global Dystonia Rating Scale as a predictor of unfavorable outcomes among acute antipsychotics poisoned patients. Drug and Chemical Toxicology 2024; 47(4) doi: 10.1080/01480545.2024.2313561
|
| 8 |
Swapnajeet Sahoo, Vanteemar S. Sreeraj, Ganesan Gopalakrishnan, Shahul Ameen, Rashmin M. Cholera, Ganesan Venkatasubramanian, Savita Malhotra. Clinical practice guidelines for management of schizophrenia in India: A comprehensive overview. Indian Journal of Psychiatry 2026; 68(1) doi: 10.4103/indianjpsychiatry_1341_25
|
| 9 |
Alexandre Hudon, Kingsada Phraxayavong, Stéphane Potvin, Alexandre Dumais. Ensemble Methods to Optimize Automated Text Classification in Avatar Therapy. BioMedInformatics 2024; 4(1) doi: 10.3390/biomedinformatics4010024
|
| 10 |
Marina Youykheang, Zaki Al Hallaq, Kenny Menelas, Robert S. Biskin, Vincent Dagenais-Beaulé. Combination of Long-Acting Injectable Antipsychotics in the Treatment of Psychiatric Disorders—A Systematic Review of the Literature and Case Series. Journal of Clinical Psychopharmacology 2023; 43(1) doi: 10.1097/JCP.0000000000001627
|
| 11 |
Laura Frankow, Chad A Bousman, Nickie Mathew, Reza Rafizadeh. Clozapine Therapy With or Without Antipsychotic Augmentation: A Retrospective Evaluation of Prescribing Practices in a Canadian Provincial Residential Treatment Centre for Concurrent Disorders: Traitement par la clozapine avec ou sans intensification à l’aide d’antipsychotiques : évaluation rétrospective des pratiques de prescription dans un centre de traitement résidentiel provincial canadien pour les troubles concomitants. The Canadian Journal of Psychiatry 2026; 71(3) doi: 10.1177/07067437251408172
|
| 12 |
|
| 13 |
Alivery Raihanada Armando, Achmad Fahmi, Heri Subianto, Agus Turchan, Wei Wang, Youheng Peng, Muhammad Fadhil Kamaruddin, Ramidha Syaharani, Ramadhani Rizki Zamzam, Nathania Maulina. Deep brain stimulation for clozapine-resistant schizophrenia: a systematic review of target-specific outcomes and stereotactic technical considerations. Neurosurgical Review 2026; 49(1) doi: 10.1007/s10143-026-04296-9
|
| 14 |
Inmaculada Baeza, Adriana Fortea, Daniel Ilzarbe, Gisela Sugranyes. What Role for Long-Acting Injectable Antipsychotics in Managing Schizophrenia Spectrum Disorders in Children and Adolescents? A Systematic Review. Pediatric Drugs 2023; 25(2) doi: 10.1007/s40272-023-00558-x
|
| 15 |
Ta-Chun Lin, Ching-Hua Lin. Schizophrenia Patients Discharged on Clozapine Plus Long-Acting Injectable Antipsychotics From a Public Psychiatric Hospital in Taiwan, 2006–2021. International Journal of Neuropsychopharmacology 2023; 26(11) doi: 10.1093/ijnp/pyad053
|
| 16 |
Sandeep Grover, Jyotika Kanwar, Subho Chakrabarti. Use of a Combination of Clozapine With a Long-Acting Injectable Antipsychotic. Journal of Clinical Psychopharmacology 2026; doi: 10.1097/JCP.0000000000002177
|
| 17 |
Takahiko Nagamine. Optimizing Management of Treatment‐Resistant Schizophrenia in Japan: Promoting a Refined Clozapine Titration Protocol and Addressing the ‘Clozapine Ceiling’ through Glutamatergic Modulation. Psychiatry and Clinical Neurosciences 2026; doi: 10.1111/pcn.70093
|
| 18 |
Zijin Feng, Zhijing Hu, Lei Li, Minquan Yu, Yiting Zhang, Peng Jing, Xiangqing Xu, Jinhui Wu, Yiqiao Hu, Xiangyang Xu. Assessing NH300094, a novel dopamine and serotonin receptor modulator with cognitive enhancement property for treating schizophrenia. Frontiers in Pharmacology 2024; 15 doi: 10.3389/fphar.2024.1298061
|
| 19 |
V. G. Kaleda, V. F. Mokhov, D. V. Tikhonov, I. S. Lebedeva, T. N. Krasnova, T. V. Beketova, E. L. Nasonov. Autoimmune problems of resistant schizophrenia: Lessons from rheumatology. Rheumatology Science and Practice 2025; 63(6) doi: 10.47360/1995-4484-2025-552-558
|
| 20 |
Sumaila Asif, Jigyansa Ipsita Pattnaik, Ipsita Debata, Sudipta Kumar Das, Jayaprakash Russell Ravan, Swayanka Samantaray, Ramakant Swain. Predictors of clozapine efficacy in treatment-resistant schizophrenia: A cross-sectional analysis of sociodemographic, clinical, biochemical, and electrophysiological EEG changes. Archives of Mental Health 2024; 25(2) doi: 10.4103/amh.amh_188_23
|
| 21 |
Sofia Pappa, Réka Csehi, Ellice Caldwell-Dunn, Zsófia Borbála Dombi, Stephan Hjorth. Cariprazine and clozapine: a systematic review of a promising antipsychotic combination for treatment-resistant schizophrenia. International Journal of Neuropsychopharmacology 2025; 28(8) doi: 10.1093/ijnp/pyaf053
|
| 22 |
Archana Mishra, Rituparna Maiti, Mathan kumar Ramasubbu, Anand Srinivasan. Evaluation of the pharmacodynamic interaction effect of augmentation agents with clozapine in patients with treatment-resistant schizophrenia: A simulation study of clinical data. Psychiatry Research 2024; 338 doi: 10.1016/j.psychres.2024.115989
|
| 23 |
Liang Lv, Meng-Yun Guan. Intracranial hypertension after MECT: successful transition to rTMS for refractory auditory hallucinations: a case report. Frontiers in Psychiatry 2026; 17 doi: 10.3389/fpsyt.2026.1841894
|
| 24 |
Naveen Chandrashekar Hegde, Biswa Ranjan Mishra, Debadatta Mohapatra, Anand Srinivasan, Rituparna Maiti. Augmentation of clozapine with dextromethorphan in treatment-resistant schizophrenia: A randomized, group sequential adaptive design, controlled clinical trial. Asian Journal of Psychiatry 2026; 119 doi: 10.1016/j.ajp.2026.104919
|
| 25 |
Marco De Pieri. Strategic and tactic use of antipsychotic medications in schizophrenia: a perspective on current prescription practice. Discover Mental Health 2025; 5(1) doi: 10.1007/s44192-025-00283-6
|
| 26 |
Sukriti Mukherjee, Jayashree Kalita, Trishita Chatterjee, Zinedine Zidane, Sukanto Sarkar. Exploring adjunctive continuous theta burst stimulation for treatment-resistant auditory hallucinations in schizophrenia: Insights from a case series. Indian Journal of Psychiatry 2025; 67(6) doi: 10.4103/indianjpsychiatry.indianjpsychiatry_200_25
|
| 27 |
Advances in Social Networks Analysis and Mining. Lecture Notes in Social Networks 2026; doi: 10.1007/978-3-032-13509-4_12
|
| 28 |
Pasindu Wickramarachchi, Jessica M. Boyd, Dennis J. Orton. Biological variation in clozapine and metabolite reporting during therapeutic drug monitoring. Clinica Chimica Acta 2022; 531 doi: 10.1016/j.cca.2022.04.005
|
| 29 |
Letizia Biso, Marco Carli, Marco Scarselli, Biancamaria Longoni. Overview of Novel Antipsychotic Drugs: State of the Art, New Mechanisms, and Clinical Aspects of Promising Compounds. Biomedicines 2025; 13(1) doi: 10.3390/biomedicines13010085
|
| 30 |
Gabriel Mendes Costa. Radiofrequency Ablation of the Ventromedial Shell of the Nucleus Accumbens as a Therapeutic Method Applied to Clozapine-Resistant Schizophrenia
. Arquivos Brasileiros de Neurocirurgia: Brazilian Neurosurgery 2026; 45(01) doi: 10.1055/s-0046-1819590
|
| 31 |
Octavian Vasiliu. Third-generation antipsychotics in patients with schizophrenia and non-responsivity or intolerance to clozapine regimen: What is the evidence?. Frontiers in Psychiatry 2022; 13 doi: 10.3389/fpsyt.2022.1069432
|
| 32 |
João Guilherme de Moraes Pontes, João Victor Silva Nani, Banny Silva Barbosa Correia, Tássia Brena Barroso Carneiro Costa, Danijela Stanisic, Mirian A. F. Hayashi, Ljubica Tasic. An Investigation of the Sodium Nitroprusside Effects on Serum Lipids in an Animal Model of Schizophrenia by the Magnetic Resonance Study. ACS Omega 2024; 9(49) doi: 10.1021/acsomega.4c07072
|
| 33 |
Amity Honor, Joseph Parmenter, Rodney Marsh, Dan Siskind, Nicola Warren. Clozapine and anti-cancer agents: a systematic literature review of case reports. CNS Spectrums 2025; 30(1) doi: 10.1017/S1092852925100576
|
| 34 |
Andrea de Bartolomeis, Mariateresa Ciccarelli, Licia Vellucci, Michele Fornaro, Felice Iasevoli, Annarita Barone. Update on novel antipsychotics and pharmacological strategies for treatment-resistant schizophrenia. Expert Opinion on Pharmacotherapy 2022; 23(18) doi: 10.1080/14656566.2022.2145884
|
| 35 |
Jin Li, Tingting Jin, Yuyan Chi, Jie Chen, Ju Gao, Yong Yang, Qing Tian, Xiaobin Zhang, Limei Zheng. Magnetic Seizure Therapy vs Electroconvulsive Therapy in Schizophrenia: Prefrontal-Amygdala Plasticity and Cognitive Safety. Neuropsychiatric Disease and Treatment 2025; doi: 10.2147/NDT.S531892
|
| 36 |
Ravi Philip Rajkumar. The Advantages of Combining Therapies in Treating Psychiatric Patients. Brain Sciences 2024; 14(7) doi: 10.3390/brainsci14070708
|
| 37 |
Peijuan Wang, Chao Liu, Xueyan Zhu, Qi Yan, Ning Shen, Jiajia Shi, Qinyu Lv, Xiangdong Du. A clinical control study of modified electroconvulsive therapy and sodium valproate as enhancement strategies for ultra-treatment-resistant schizophrenia. Schizophrenia Research: Cognition 2026; 43 doi: 10.1016/j.scog.2025.100396
|
| 38 |
Martina Nováková, Tomáš Hammer, Eliška Nováková, Michaela Mayerová, Libor Ustohal, Hana Kotolová. Potential impact on mental health in patients with treatment-resistant schizophrenia - clozapine augmentation with long-acting parenteral antipsychotics: a case series. Česká a slovenská farmacie 2023; 72(6) doi: 10.5817/CSF2023-6-276
|
| 39 |
Irina Vladimirovna Dubatova, Lema Andreevich Antsyborov, Artur Fedorovich Kheigetian, Andrey Viktorovich Antsyborov. “Golden Shot” in the Treatment and Diagnosis of Schizophrenia: Psychiatrists or Neuroscientists?. Interactive science 2021; (10 (65)) doi: 10.21661/r-555399
|
| 40 |
Mohsen Khosravi. Effectiveness of deep brain stimulation in alleviating treatment-resistant schizophrenia: a systematic review. European Journal of Translational Myology 2025; 35(3) doi: 10.4081/ejtm.2025.14206
|
| 41 |
Laura Orsolini, Silvia Bellagamba, Virginio Salvi, Umberto Volpe. A case report of clozapine-treatment-resistant schizophrenia successfully managed with brexpiprazole combination therapy. Asian Journal of Psychiatry 2022; 72 doi: 10.1016/j.ajp.2022.103121
|
| 42 |
Jin Li, Junjie Wang, Yong Yang, Ju Gao, Xiaobin Zhang. The Effect of Electroconvulsive and Magnetic Seizure Therapy (MST) on Cortical Thickness in Schizophrenia. CNS Neuroscience & Therapeutics 2025; 31(3) doi: 10.1111/cns.70309
|
| 43 |
Partha Das, Emma Robertson, Victoria Harpwood, Stephanie Tierney. Psychosocial and Forensic Characteristics of Adult Mental Health Patients Referred to an Australian Secure Extended Care Unit and Predictors of Acceptance. International Journal of Social Psychiatry 2026; doi: 10.1177/00207640261439746
|
| 44 |
Soumitra Das, Annie Itrat, Mary Elizabeth Trejo Hernandez, Rasish Subedi, Thusanth Jogarajah, Sreshatha Vashist, Nikitha Daggala. Clozapine-induced eosinophilia: A case report. SAGE Open Medical Case Reports 2023; 11 doi: 10.1177/2050313X231195961
|
| 45 |
Sandeep Grover, Sanjana Kathiravan. Clozapine research from India: A systematic review. Asian Journal of Psychiatry 2023; 79 doi: 10.1016/j.ajp.2022.103353
|
| 46 |
Pierre-Michel Llorca, Philippe Nuss, Éric Fakra, Isabelle Alamome, Dominique Drapier, Wissam El Hage, Renaud Jardri, Stéphane Mouchabac, Marc Rabbani, Nicolas Simon, Marie-Noëlle Vacheron, Jean-Michel Azorin. Place of the partial dopamine receptor agonist aripiprazole in the management of schizophrenia in adults: a Delphi consensus study. BMC Psychiatry 2022; 22(1) doi: 10.1186/s12888-022-04008-9
|
| 47 |
Marcin Siwek, Adrian Andrzej Chrobak, Aleksandra Gorostowicz, Patrycja Król, Dominika Dudek. Lurasidone Augmentation of Clozapine in Schizophrenia—Retrospective Chart Review. Brain Sciences 2023; 13(3) doi: 10.3390/brainsci13030445
|
| 48 |
Vanessa M. Dang, John M. Powers, Matej Markota, Jonathan G. Leung. Adjunctive xanomeline/trospium in clozapine-resistant schizophrenia: two case reports demonstrating limited response. Therapeutic Advances in Psychopharmacology 2026; 16 doi: 10.1177/20451253261433832
|
| 49 |
Kazuki Nishida, Basile Chrétien. Comment on: Is clozapine use a risk of hematological malignancies? Insights from a meta‐analysis “Clozapine and Malignancy Risk”. Psychiatry and Clinical Neurosciences 2025; 79(9) doi: 10.1111/pcn.13839
|
| 50 |
Cristiano Chaves, Jennifer Fabe, Fabiano A. Gomes, Heather McNeely, Massimo Tusconi, Mauro Giovanni Carta, Serdar M. Dursun, Jaime E. C. Hallak, Elisa Brietzke. Ketogenic therapy for schizophrenia: evidence, mechanisms, and clinical perspectives. Frontiers in Pharmacology 2025; 16 doi: 10.3389/fphar.2025.1603722
|
| 51 |
A. R. Asadullin, P. O. Bomov, Yu. A. Bogod. Use of third-generation antipsychotics in combination with clozapine in the treatment of resistant schizophrenia. V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY 2025; 59(2) doi: 10.31363/2313-7053-2025-2-1147
|
| 52 |
Anxin Wen. Beyond symptom reduction: Positioning dextromethorphan as a post-optimization strategy in clozapine-treated treatment-resistant schizophrenia. Asian Journal of Psychiatry 2026; 120 doi: 10.1016/j.ajp.2026.104992
|
| 53 |
Sung Moon Choi, Myung Jae Baik, Won Sub Kang, Ah Rah Lee, Jong Woo Paik, Sang Min Lee. Factors Affecting Clozapine Adherence in Patients With Schizophrenia: A Qualitative Study. Journal of Korean Neuropsychiatric Association 2025; 64(4) doi: 10.4306/jknpa.2025.64.4.277
|
| 54 |
Noora Tuovinen, Alex Hofer. Resting-state functional MRI in treatment-resistant schizophrenia. Frontiers in Neuroimaging 2023; 2 doi: 10.3389/fnimg.2023.1127508
|
| 55 |
Tanya Paul, Jia Whei See, Vetrivel Vijayakumar, Temiloluwa Njideaka-Kevin, Hanyou Loh, Vivian Jia Qi Lee, Bekir Nihat Dogrul. Neurostructural changes in schizophrenia and treatment-resistance: a narrative review. Psychoradiology 2024; 4 doi: 10.1093/psyrad/kkae015
|
| 56 |
Vjekoslav Peitl, Antonia Puljić, Mislav Škrobo, Sergej Nadalin, Lidija Fumić Dunkić, Dalibor Karlović. Clozapine in Treatment-Resistant Schizophrenia and Its Augmentation with Electroconvulsive Therapy in Ultra-Treatment-Resistant Schizophrenia. Biomedicines 2023; 11(4) doi: 10.3390/biomedicines11041072
|
| 57 |
Jae Hee Cho, Hindol Mukherjee, Vladimir Sazhin. Is antipsychotic augmentation associated with improved functioning in patients on clozapine?. Australasian Psychiatry 2024; 32(3) doi: 10.1177/10398562241232819
|
| 58 |
Alexandre Hudon, Mélissa Beaudoin, Kingsada Phraxayavong, Stéphane Potvin, Alexandre Dumais. Enhancing Predictive Power: Integrating a Linear Support Vector Classifier with Logistic Regression for Patient Outcome Prognosis in Virtual Reality Therapy for Treatment-Resistant Schizophrenia. Journal of Personalized Medicine 2023; 13(12) doi: 10.3390/jpm13121660
|
| 59 |
Sumeet Gupta, Samuel Mammolotti Parkinson. Management of sedation due to clozapine. BJPsych Advances 2023; 29(4) doi: 10.1192/bja.2022.27
|
| 60 |
Partha Das, Emma Robertson, Victoria Harpwood, Stephanie Tierney. Social demographics and clinical characteristics of referred adult mental health patients to an Australian secure extended care unit: A 5-year retrospective study. International Journal of Social Psychiatry 2025; 71(8) doi: 10.1177/00207640251343171
|
| 61 |
Carol Lim, Abigail L Donovan. Treatment paradigms for treatment-resistant schizophrenia. The Lancet Psychiatry 2024; 11(7) doi: 10.1016/S2215-0366(24)00173-1
|
| 62 |
Federica Tralongo, Céline Konecki, Catherine Feliu, Arthur Kaladjian, Zoubir Djerada. Association Between Clozapine Plasma Concentrations and Treatment Response: A Systematic Review, Meta-analysis and Individual Participant Data Meta-analysis. Clinical Pharmacokinetics 2023; 62(6) doi: 10.1007/s40262-023-01247-1
|